- Home
- NUVB vs NVCR Comparison
NUVB vs NVCR Comparison
Compare NUVB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- NVCR
- Stock Information
- Founded
- NUVB 2018
- NVCR 2000
- Country
- NUVB United States
- NVCR Switzerland
- Employees
- NUVB N/A
- NVCR N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- NUVB Health Care
- NVCR Health Care
- Exchange
- NUVB Nasdaq
- NVCR Nasdaq
- Market Cap
- NUVB 1.6B
- NVCR 1.4B
- IPO Year
- NUVB N/A
- NVCR 2015
- Fundamental
- Price
- NUVB $4.62
- NVCR $10.96
- Analyst Decision
- NUVB Strong Buy
- NVCR Buy
- Analyst Count
- NUVB 7
- NVCR 7
- Target Price
- NUVB $8.86
- NVCR $28.64
- AVG Volume (30 Days)
- NUVB 9.4M
- NVCR 1.4M
- Earning Date
- NUVB 11-03-2025
- NVCR 10-30-2025
- Dividend Yield
- NUVB N/A
- NVCR N/A
- EPS Growth
- NUVB N/A
- NVCR N/A
- EPS
- NUVB N/A
- NVCR N/A
- Revenue
- NUVB $26,748,000.00
- NVCR $642,269,000.00
- Revenue This Year
- NUVB $283.17
- NVCR $9.54
- Revenue Next Year
- NUVB $340.98
- NVCR $5.70
- P/E Ratio
- NUVB N/A
- NVCR N/A
- Revenue Growth
- NUVB 1137.19
- NVCR 11.17
- 52 Week Low
- NUVB $1.54
- NVCR $10.70
- 52 Week High
- NUVB $5.55
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- NUVB 55.23
- NVCR 31.43
- Support Level
- NUVB $4.45
- NVCR $10.70
- Resistance Level
- NUVB $5.17
- NVCR $14.22
- Average True Range (ATR)
- NUVB 0.44
- NVCR 0.55
- MACD
- NUVB -0.05
- NVCR -0.29
- Stochastic Oscillator
- NUVB 44.17
- NVCR 15.26
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.